Our study also suggested that glioblastoma cells were reliant on this mechanism to escape clinical treatment through drug resistance; therefore, RECQ1-PARP1 signaling may be a suitable target for GBM tumor therapy. This evidence concerns the gene RECQL and glioblastoma.